 WALTHAM, Mass., Dec. 14, 2020 GLOBE NEWSWIRE -- AMAG Pharmaceuticals, Inc. has submitted its response to the FDAs Notice of Opportunity for a Hearing NOOH regarding the Agencys proposal to withdraw approval for Makenaalso referred to as 17-OHPCthe only FDA-approved treatment, along with five generic versions, to reduce preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. 